Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 276.11M P/E - EPS this Y 48.70% Ern Qtrly Grth -
Income -130.71M Forward P/E -3.95 EPS next Y 34.60% 50D Avg Chg -12.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 21.00%
Dividend N/A Price/Book 4.11 EPS next 5Y - 52W High Chg -32.00%
Recommedations 1.70 Quick Ratio 6.39 Shares Outstanding 164.42M 52W Low Chg 168.00%
Insider Own 0.85% ROA -49.54% Shares Float 132.69M Beta 0.28
Inst Own 68.64% ROE -267.24% Shares Shorted/Prior 10.29M/12.05M Price 1.74
Gross Margin - Profit Margin - Avg. Volume 3,643,658 Target Price 3.51
Oper. Margin - Earnings Date Nov 1 Volume 1,671,654 Change 0.00%
About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

X4 Pharmaceuticals, Inc. News
09/19/23 X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
09/06/23 X4 Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
09/05/23 X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome
09/01/23 X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/15/23 XFOR: NDA for Mavorixafor in WHIM Syndrome in Early 2H23…
08/10/23 X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program
08/08/23 X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer
08/03/23 X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital
08/02/23 X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023
06/14/23 XFOR: Initiating Coverage of X4 Pharmaceuticals; Investing on More Than Just a WHIM…
06/13/23 X4 Pharmaceuticals Expected to Join Russell 3000® Index
05/16/23 X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome
05/16/23 X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
05/15/23 Weekly biotech pulse: X4 Pharma data on deck, AbbVie set for FDA review
05/04/23 X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update
04/26/23 X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are retail investors with 42% ownership, institutions own 32%
04/26/23 X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023
04/12/23 X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS)
03/24/23 X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2022 Earnings Call Transcript
03/21/23 X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
XFOR Chatroom

User Image Investor697 Posted - 1 day ago

$XFOR Got my eye on this, really like it !

User Image stealin_your_thunder Posted - 3 days ago

$XFOR catching nice bid imo.

User Image GXD_Everywhere Posted - 3 days ago

@Trainguy1 @Diceroller28 $MIRM , $APLS $IOVA is cheap, $XFOR is cheap, & your $VRNA is looking nice for entry, looks like great support too.

User Image AG_Trader10 Posted - 4 days ago

$XFOR Listen to the last fireside chat and this is an easy buy. Looking forward to the Cantor cc on the 26th.

User Image NT72 Posted - 4 days ago

@stealin_your_thunder $XFOR Me as well! GLTA.

User Image stealin_your_thunder Posted - 4 days ago

$XFOR bought back in today

User Image CEOofstocks Posted - 4 days ago

$XFOR almost there. Question is, will $0.96 double bottom hold, or will we see a break and retest of old support at $0.78? I have to rewatch the last CC as it seemed to be the catalyst towards the negativity, especially the few clients reported on.

User Image Enab001 Posted - 4 days ago

$XFOR

User Image AG_Trader10 Posted - 4 days ago

$XFOR Adding

User Image Rollercoaster22 Posted - 4 days ago

$XFOR Tired of this pos.

User Image LilloG Posted - 5 days ago

$CRDL $ESPR $XFOR not going to well , XFOR in phase 3 i think gonna go below 1 $ soon.

User Image talkin_stocks Posted - 5 days ago

Stock Moving Biotech Catalysts to Watch • $ZVRA Ph 2 data • $PLRX Ph 2 data • $XFOR Ph 2 data

User Image Stock_Titan Posted - 6 days ago

$XFOR X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-to-participate-in-the-cantor-global-healthcare-zfbgiaofz00m.html

User Image AG_Trader10 Posted - 1 week ago

$XFOR Why the move down?

User Image St0ckt0k101 Posted - 1 week ago

$XFOR who dropped this after I got in at $1.22! Buying more if it goes below $1 again!

User Image WizeKing Posted - 1 week ago

$XFOR Next catalyst?

User Image Jabed206 Posted - 1 week ago

$XFOR 50% down over last 3 months

User Image Rollercoaster22 Posted - 1 week ago

$XFOR Is it manipulation? Sell off? Thought it would recover.

User Image Rollercoaster22 Posted - 1 week ago

$XFOR What the h-ll is going on? So tired of seeing this ticker going down the drain.

User Image Capitulation_0 Posted - 1 week ago

$XFOR Biotwitter searching for answers.

User Image aymat Posted - 1 week ago

$XFOR @CEOofstocks u right. This might be going below $1 until news. Will wait til then. Vanguard, BlackRock, State Street, Bain Cap, AXA, etc. all holding. CN news will be most groundbreaking and the life saver here. WHIM is a joke but will give company familiarity with FDA + process. Long hold. Also, Paula if you’re reading this, stop selling your shares if you’re trying to inspire confidence in the meantime, genius.

User Image AG_Trader10 Posted - 1 week ago

$XFOR For those that watched the webcast. What indication was the discussion on partners with?

User Image Capitulation_0 Posted - 1 week ago

$XFOR $1 holla soon.

User Image Capitulation_0 Posted - 1 week ago

$XFOR trading like it's headed for BK. Biotwitter does it again.

User Image Falstaff Posted - 1 week ago

$XFOR did anyone watch the webcast?

User Image aymat Posted - 1 week ago

$XFOR also Paula, the CEO, has a lot of stock awarded but she seems to be selling weekly. My bet is she is supplementing a lifestyle in anticipation of a boom in the company. What does she know? Will re-enter at $0.88 if we get there. But hopefully in next 50 days hear back from FDA.

User Image aymat Posted - 1 week ago

$XFOR below moving averages. I expected some bounce post conference. Anyone listen? I honestly could care less about WHIM as there are a few hundred cases globally, but if this leads to higher drug prices and the bigger target of focusing on immune system compromises, then this thing could be huge.

User Image MarketBeatInsiderTrades Posted - 1 week ago

X4 Pharmaceuticals COO Mary Dibiase Sells $3,302.50 in $XFOR www.marketbeat.com/stocks/NASDAQ/XFOR/insider-trades/

User Image cctranscripts Posted - 1 week ago

X4 Pharmaceuticals, Inc's Chief Operating Officer just disposed of 2,642 shares https://www.conferencecalltranscripts.org/summary/?id=12533404 $XFOR

User Image pdolum Posted - 1 week ago

$XFOR Hopefully some positive update tomorrow

Analyst Ratings
HC Wainwright & Co. Buy Aug 11, 23
Stifel Buy May 17, 23
HC Wainwright & Co. Buy May 5, 23
B. Riley Securities Buy Apr 10, 23
Oppenheimer Outperform Mar 24, 23
Cantor Fitzgerald Overweight Mar 22, 23
HC Wainwright & Co. Buy Mar 22, 23
Cantor Fitzgerald Overweight Dec 22, 22
Piper Sandler Overweight Dec 12, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
WYZGA MICHAEL S Director Director Aug 18 Buy 1.195 25,000 29,875 76,667 08/22/23
Stewart Murray Interim Chief Medica.. Interim Chief Medical Officer Aug 09 Sell 1.06 130,056 137,859 146,504 08/11/23
Ragan Paula President and CEO President and CEO May 31 Sell 1.95 6,292 12,269 557,245 05/31/23
Ragan Paula President and CEO President and CEO Jun 03 Sell 1.21 6,292 7,613 661,806 06/06/22